Helmut Jonuleit
Overview
Explore the profile of Helmut Jonuleit including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
2264
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Riegel K, Yurugi H, Schloder J, Jonuleit H, Kaulich M, Kirschner F, et al.
Cell Death Dis
. 2021 Oct;
12(11):969.
PMID: 34671021
Tumors exhibit a variety of strategies to dampen antitumor immune responses. With an aim to identify factors that are secreted from tumor cells, we performed an unbiased mass spectrometry-based secretome...
2.
Satoh K, Kobayashi Y, Fujimaki K, Hayashi S, Ishida S, Sugiyama D, et al.
Int Immunol
. 2021 Jul;
33(8):435-446.
PMID: 34235533
Regulatory T (Treg) cells, which are essential for maintaining self-tolerance, inhibit anti-tumor immunity, consequently hindering protective cancer immunosurveillance, and hampering effective anti-tumor immune responses in tumor-bearing hosts. Here, we show...
3.
Schupp J, Christians A, Zimmer N, Gleue L, Jonuleit H, Helm M, et al.
Int J Mol Sci
. 2021 Jan;
22(3).
PMID: 33498319
The presence and interaction of immune cells in the tumor microenvironment is of significant importance and has a great impact on disease progression and response to therapy. Hence, their identification...
4.
Bogucka K, Marini F, Rosigkeit S, Schloeder J, Jonuleit H, David K, et al.
Cancer Gene Ther
. 2020 Nov;
28(5):543.
PMID: 33168935
No abstract available.
5.
Bogucka K, Marini F, Rosigkeit S, Schloeder J, Jonuleit H, David K, et al.
Cancer Gene Ther
. 2020 Oct;
28(5):359-374.
PMID: 33070159
KRAS is one of the most frequently mutated oncogenes, especially in lung cancers. Targeting of KRAS directly or the downstream effector signaling machinery is of prime interest in treating lung...
6.
Riegel K, Schloder J, Sobczak M, Jonuleit H, Thiede B, Schild H, et al.
Cell Death Differ
. 2019 Sep;
27(4):1300-1315.
PMID: 31541179
RAF kinases (ARAF, BRAF, and CRAF) are highly conserved enzymes that trigger the RAF-MEK1/2-ERK1/2 (MAPK) pathway upon activation of RAS. Despite enormous clinical interest, relatively little is known on the...
7.
Pektor S, Schloder J, Klasen B, Bausbacher N, Wagner D, Schreckenberger M, et al.
Eur J Nucl Med Mol Imaging
. 2019 Sep;
47(5):1314-1325.
PMID: 31471714
Purpose: Hematopoietic stem cell transplantation is the only curative treatment for several hematological malignancies and immune deficiency syndromes. Nevertheless, the development of graft-versus-host disease (GvHD) after transplantation is a severe...
8.
Fischer M, Schermann A, Twelkmeyer T, Lorenz B, Wegner J, Jonuleit H, et al.
Exp Dermatol
. 2019 Jul;
28(9):1087-1090.
PMID: 31260571
Humanized mice represent a suitable preclinical test system for example therapeutic interventions in various disease settings, including infections. Here, we intended to establish such system for cutaneous leishmaniasis by infecting...
9.
Schloder J, Berges C, Tuettenberg A, Jonuleit H
Front Immunol
. 2017 Nov;
8:1495.
PMID: 29167672
Allogeneic hematopoietic stem cell transplantation is the only curative treatment option for several hematological malignancies and immune deficiency syndromes. Nevertheless, the development of a graft-versus-host disease (GvHD) after transplantation is...
10.
van Ham M, Teich R, Philipsen L, Niemz J, Amsberg N, Wissing J, et al.
Eur J Immunol
. 2017 Aug;
47(12):2043-2058.
PMID: 28833060
Regulatory T (Treg) cells require T-cell receptor (TCR) signalling to exert their immunosuppressive activity, but the precise organization of the TCR signalling network compared to conventional T (Tconv) cells remains...